0001193125-21-103380.txt : 20210401 0001193125-21-103380.hdr.sgml : 20210401 20210401091557 ACCESSION NUMBER: 0001193125-21-103380 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210329 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210401 DATE AS OF CHANGE: 20210401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunityBio, Inc. CENTRAL INDEX KEY: 0001326110 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 431979754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37507 FILM NUMBER: 21796255 BUSINESS ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 633-0300 MAIL ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NantKwest, Inc. DATE OF NAME CHANGE: 20150713 FORMER COMPANY: FORMER CONFORMED NAME: Conkwest, Inc. DATE OF NAME CHANGE: 20140416 FORMER COMPANY: FORMER CONFORMED NAME: ZelleRx Corp DATE OF NAME CHANGE: 20050504 8-K 1 d140635d8k.htm 8-K 8-K
false 0001326110 0001326110 2021-03-29 2021-03-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 29, 2021

 

 

ImmunityBio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37507   43-1979754
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

3530 John Hopkins Court

San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 633-0300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   IBRX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) Resignations from the Board of Directors

On March 29, 2021, the following members of the board of directors (the “Board”) of ImmunityBio, Inc. (the “Company”) notified the Board of their decision to resign from the Board, effective March 29, 2021: John C. Thomas Jr. and Frederick W. Driscoll (collectively, the “Resigning Directors”). Mr. Thomas is also resigning as chairperson of the audit and related party transaction committees of the Board and as a member of the compensation committee of the Board. Mr. Driscoll is also resigning as a member of each of the audit, compensation, and related party transaction committees of the Board. The resignations of the Resigning Directors were for personal reasons and were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

(d) Appointment to the Board of Directors

On March 29, 2021, the Board appointed Linda Maxwell, M.D., M.B.A., to the Board, effective immediately, with a term expiring at the Company’s 2021 annual meeting of stockholders. Dr. Maxwell will also serve as a member of the audit committee of the Board and chairperson of the compensation committee of the Board.

Dr. Maxwell has been a head and neck surgeon since 2006, and is a medical educator, a published scientific author, and a health technology entrepreneur and innovator. Currently, Dr. Maxwell is Adjunct Professor of Surgery at the University of Toronto, Distinguished Visiting Professor at Ryerson University, and Associate Scientist at the Li Ka Shing Knowledge Institute in Toronto. She served as Founding and Executive Director of the Biomedical Zone in 2015 – Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies – and has guided a wide variety of startup companies through clinical development, capitalization, and commercialization. Dr. Maxwell also managed a life sciences tech transfer portfolio at the University of Oxford and the UK National Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert to various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee of the Public Health Agency of Canada, and as an advisor to the Canadian Medical Association and the Canadian Space Agency. Dr. Maxwell earned an A.B. with honors from Harvard University, an M.D. from Yale University, and an M.B.A. from the University of Oxford. Dr. Maxwell currently serves on the board of United Therapeutics Corporation.

Dr. Maxwell is entitled to receive cash compensation in accordance with the terms and conditions of the Company’s Outside Director Compensation Policy. Under the Outside Director Compensation Policy, each non-employee director receives cash compensation of $50,000 annually for service as a Board member; $10,000 per year additionally for service as an audit committee member; $15,000 per year additionally for service as a special committee member; $7,500 per year additionally for service as a member of the other committees; $10,000 per year additionally for service as chairperson of the audit committee; $15,000 per year additionally for service as chairperson of the special committee; and $7,500 per year additionally for service as chairperson of the other committees. We will also reimburse Dr. Maxwell for all reasonable expenses in connection with her services to us. In addition, the Board will consider equity compensation for Dr. Maxwell consistent with past practice.

Dr. Maxwell executed the Company’s standard form of indemnification agreement, which form has been filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-205124) filed with the Securities and Exchange Commission on June 19, 2015 and is incorporated herein in its entirety by reference.

There is no arrangement or understanding between Dr. Maxwell and any other persons pursuant to which Dr. Maxwell was selected as a director. In addition, Dr. Maxwell is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

On March 29, 2021, the Board appointed Richard Adcock, our Chief Executive Officer, to the Board, effective immediately, with a term expiring at the Company’s 2021 annual meeting of stockholders.


Mr. Adcock has served as our Chief Executive Officer since October 2020. From January 2018 to September 2020, Mr. Adcock was chief executive officer of Verity Health Systems, a California-based nonprofit healthcare system that he steered through a successful restructuring event. Prior to joining Verity Health, Mr. Adcock served in various capacities at Sanford Health, including as its chief innovation officer, president, executive vice president and director from 2004 to 2017. Sanford Health is the largest rural nonprofit healthcare system in the U.S. with more than 382 locations and 28,000 employees. While at Sanford Health, Mr. Adcock was responsible for leading the healthcare company’s growth and innovation, in addition to direct operational oversight of related entities including Sanford Research, Sanford Health Plan, Sanford Foundation and Sanford Frontiers. During his time at Sanford Health, Mr. Adcock learned first-hand how essential it is to keep the patient at the center of all healthcare decisions. This was even more important as Sanford Health brought forth many new exciting treatments, therapies and medical devices from their own research efforts. Prior to Sanford Health, Mr. Adcock served as global engineering director at GE Healthcare from 1999 to 2003. Mr. Adcock began his career in the medical field as co-owner and vice president of research and development at medical equipment supplier Micro Medical Systems.

As an employee director, Mr. Adcock will not receive additional compensation as a result of his appointment as a director of the Company.

Mr. Adcock executed the Company’s standard form of indemnification agreement, which form has been filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333- 205124) filed with the Securities and Exchange Commission on June 19, 2015 and is incorporated herein in its entirety by reference.

There is no arrangement or understanding between Mr. Adcock and any other persons pursuant to which Mr. Adcock was selected as a director. In addition, Mr. Adcock is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company issued a press release announcing the appointment of Dr. Maxwell and Mr. Adcock to the Board. A copy of this press release is attached hereto as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit
Number

  

Exhibit Title

99.1    Press release of ImmunityBio, Inc. dated April 1, 2021.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      IMMUNITYBIO, INC.

Date: April 1, 2021

    By:  

/s/ David Sachs

      Chief Financial Officer
EX-99.1 2 d140635dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

News Release

ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors

CULVER CITY, Calif., April 1, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard Adcock to the board; he was named CEO of NantKwest in October and remains the CEO of the company after the merger of NantKwest with ImmunityBio in March. Both appointments are effective March 29, 2021.

The nine-member ImmunityBio board is led by Founder and Executive Chairman Patrick Soon-Shiong, M.D. The board includes two other recently appointed outside members, former CIA director John Brennan and retired U.S. Army General Wesley Clark, along with current board members Michael Blaszyk, Cheryl Cohen, Cristobel Selecky, and Barry Simon, M.D.

“Linda’s background as a physician and surgeon combined with her extensive global healthcare industry and business experience will enable us to build on ImmunityBio’s strong foundation and help us take the company to the next level,” said Soon-Shiong. “As a company working to bring novel therapeutic approaches to treating cancer and other serious conditions, we will benefit greatly from Linda’s insights on innovation.”

The company also announced that two current directors—Fred Driscoll and John D. Thomas—will conclude their service on the board effective with the new appointments.

“We are grateful to Fred and John for their many years of service and the value they brought to our shareholders and employees,” said Soon-Shiong. “During their tenure, we have expanded our pipeline and grown our portfolio of immunotherapy agents. Their contributions during that time were important to establishing this strong foundation and baseline for the growth we anticipate.”

About Dr. Linda Maxwell

Dr. Maxwell is a medical educator, surgeon, and health technology entrepreneur and innovator. She has guided a wide variety of startup companies through clinical development capitalization and commercialization as Founder and Executive Director of the Biomedical Zone, Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies. Dr. Maxwell also managed a life sciences tech transfer portfolio at the University of Oxford and the UK national Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert in various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee and the Public Health Agency of Canada, as an advisor to the Canadian Medial Association and the Canadian Space Agency. Dr. Maxwell earned an A.B. with honors from Harvard University, an M.D. from Yale University and an M.B.A. from the University of Oxford. She serves as an independent member of the Board of Directors of United Therapeutics, Inc.

“I’m honored to join the ImmunityBio board at such an important time of growth and opportunity for the company,” she said. “I’m impressed with both the science and the leadership that I believe will take the company on an upward trajectory as it makes innovative contributions to medicine.”


About ImmunityBio

ImmunityBio is a leading, late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”

ImmunityBio has a comprehensive immunotherapy pipeline with more than 40 clinical trials (company sponsored or investigator initiated)—of which 25 are at Phase II and III stage of development—across 19 indications in solid and liquid cancers and infectious diseases. Currently 17 first-in human immunotherapy agents are in clinical testing and, to date, over 1,800 patients have been studied with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf natural killer cell products. Anktiva (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

The company’s platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells. ImmunityBio is currently developing a dual construct COVID-19 vaccine candidate using its hAd5 platform.

ImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations and development teams. For more information, please visit: www.immunitybio.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues”, “could”, “estimates,” “expects,” “intends,” “may,” “plans,” “potential”, “predicts”, “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger of NantKwest and ImmunityBio, Inc., (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the


expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or ImmunityBio’s operations or operating expenses. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 10, 2021 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Contacts

Investors

Sarah Singleton

ImmunityBio, Inc.

844-696-5235, Option 5

Media

Amy Jobe, Ph.D.

LifeSci Communications

315-879-8192

ajobe@lifescicomms.com

EX-101.SCH 3 ibrx-20210329.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ibrx-20210329_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ibrx-20210329_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g140635page1.jpg GRAPHIC begin 644 g140635page1.jpg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end XML 7 d140635d8k_htm.xml IDEA: XBRL DOCUMENT 0001326110 2021-03-29 2021-03-29 false 0001326110 8-K 2021-03-29 ImmunityBio, Inc. DE 001-37507 43-1979754 3530 John Hopkins Court San Diego CA 92121 (858) 633-0300 false false false false Common Stock, par value $0.0001 per share IBRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Mar. 29, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001326110
Document Type 8-K
Document Period End Date Mar. 29, 2021
Entity Registrant Name ImmunityBio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-37507
Entity Tax Identification Number 43-1979754
Entity Address, Address Line One 3530 John Hopkins Court
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 633-0300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol IBRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /M)@5('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #[28%22$,_(.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$[;P4R:RT9/'0Q6V-C-V&IK&L?&UDCZ]DN\-F5L#["CI=^? M/H%J':3V$5^B#QC)8KH;7-LEJ<.:'8F"!$CZB$ZE^"VAF8J[^B&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #[28%2@AW6S3D$ !&$ & 'AL+W=OK3W=N-!;!/K;GC32M%=_ MTP4>7K^IWY6=A\ZLF>%SE7X3L4VN>J,>B?F&%:E]4+N/?-^A@=.+5&K*OV17 MO=OW>R0JC%79/A@(,B&K7_:R3\1A0' D(-@'!"5W]:&2\H99-IUHM2/:O0UJ M[J+L:AD-<$*Z45E9#4\%Q-GIC8H*2+(E3,;D5EIA7\E"5J,-69MX%C[B7O6B MO>!U)1@<$?S"] 4)QFTQ?R&? M^&L;$:[D^SX-@TM*?01K4&,-4+&Z)!Y?<][&@H>/SC\A$)7.FM(+][]ZZC)(@KA+(XU-^;L[8)\AO?(5]DZE!V2X2#TR4\JD>2CRI^$-*XV MM,5P&[NFP?_"G;N6TN11[=I7$UQNQ22Y$7RK,+C&^"GNW/^&JR8&T"VU>A8R M:D\FKCF?86C-6D!/6@QJM*4R%A:%WT5^=,)V*(X#BMH=;18$BEMZ.88SV/0= M1\$%?A@-1C]B*,VR0'$W_ZPBR,HR41)SD Z1RS \]T,?6RQILQA0W,6_:6$M MEY":TLXK]S"M5+A0U[:"-FL Q;UZI5(1"2ODEGR! M>"I:T\N$HG3^/Z%+?L MI>9E>CC,L&IG 1LPV-5]W6R.C!^NUT46-/8?X%[]'[*%,060=0%VR'8"-NX? MX%:]XE&AW?2CP9H\"INV3K\.$=?#P^P*VY3M[M2Y0PN>5'-VH= M0O>SUNBQ] 6;N"+,F6S=^G<('JTU[^!4Z$[8L!'> MNK4^Y1L0\B^&X-FZ.K16#:OR\J"X5A:.G>5E @=]KMT+\'RCE'UKN+-G_:^# MZ=]02P,$% @ ^TF!4I^@&_"Q @ X@P T !X;"]S='EL97,N>&UL MW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75E MW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R M5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :# M7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T% M8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE M+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 M Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2S MP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DM MC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D M7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$ MKQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3 M\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ ^TF!4I>*NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R M!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R M'<(Y_A^[<#K3P&]'@!6^AC(, M=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,S MQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN M*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94; M4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ ^TF!4B0>FZ*M M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\ M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!: M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /M)@5)E MD'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"* MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L M^T%.6X.^D&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( /M)@5*"'=;-.00 $80 8 M " @0X( !X;"]W;W)K&PO&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #[28%299!YDAD! #/ P $P M @ &3$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" #=$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d140635d8k.htm d140635dex991.htm ibrx-20210329.xsd ibrx-20210329_lab.xml ibrx-20210329_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d140635d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d140635d8k.htm" ] }, "labelLink": { "local": [ "ibrx-20210329_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ibrx-20210329_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ibrx-20210329.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ibrx", "nsuri": "http://imetrix.edgar-online.com/20210329", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d140635d8k.htm", "contextRef": "duration_2021-03-29_to_2021-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d140635d8k.htm", "contextRef": "duration_2021-03-29_to_2021-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210329/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-21-103380-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-103380-xbrl.zip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